IMPORTANCE Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.OBJECTIVE To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a real-world population of patients with PPMS.DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, observational, retrospective,...
-
2022 (v1)PublicationUploaded on: February 14, 2024
-
2022 (v1)Publication
: Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all...
Uploaded on: April 14, 2023